Spots Global Cancer Trial Database for leukemia, acute myeloid
Every month we try and update this database with for leukemia, acute myeloid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety of Expanded Haploidentical Natural Killer Cells for Leukemia | NCT04327037 | Leukemia, Acute... Leukemia, Acute... | Expanded Haploi... IL-2 | 1 Year - 30 Years | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | |
| Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052) | NCT00687323 | Leukemia, Acute... Myelodysplastic... | temozolomide | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia | NCT02665065 | Acute Myeloid L... Leukemia, Acute... Myeloid Leukemi... Leukemia, Myelo... Acute Myelogeno... Leukemia, Acute... Myelogenous Leu... AML Bone Marrow Tra... | Iomab-B Conventional Ca... HCT | 55 Years - | Actinium Pharmaceuticals | |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | NCT05362773 | Leukemia, Acute... Myelodysplastic... Classical Hodgk... Leukemia, B-cel... Leukemia, Hairy... Mastocytosis, A... Blastic Plasmac... Chronic Myeloid... | MGD024 | 18 Years - | MacroGenics | |
| Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052) | NCT00687323 | Leukemia, Acute... Myelodysplastic... | temozolomide | 18 Years - | Merck Sharp & Dohme LLC | |
| Epigenetic Reprogramming in Relapse AML | NCT02412475 | Leukemia, Acute... | Decitabine Vorinostat Fludarabine Cytarabine Filgrastim Cytarabine Sorafenib | 1 Year - 25 Years | Medical College of Wisconsin | |
| Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation | NCT01700751 | Leukemia, Acute... Leukemia, Lymph... Myelodysplastic... | brentuximab ved... | 18 Years - 70 Years | Washington University School of Medicine | |
| Epigenetic Reprogramming in Relapse AML | NCT02412475 | Leukemia, Acute... | Decitabine Vorinostat Fludarabine Cytarabine Filgrastim Cytarabine Sorafenib | 1 Year - 25 Years | Medical College of Wisconsin | |
| Safety of Expanded Haploidentical Natural Killer Cells for Leukemia | NCT04327037 | Leukemia, Acute... Leukemia, Acute... | Expanded Haploi... IL-2 | 1 Year - 30 Years | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | NCT05362773 | Leukemia, Acute... Myelodysplastic... Classical Hodgk... Leukemia, B-cel... Leukemia, Hairy... Mastocytosis, A... Blastic Plasmac... Chronic Myeloid... | MGD024 | 18 Years - | MacroGenics | |
| Epigenetic Reprogramming in Relapse AML | NCT02412475 | Leukemia, Acute... | Decitabine Vorinostat Fludarabine Cytarabine Filgrastim Cytarabine Sorafenib | 1 Year - 25 Years | Medical College of Wisconsin |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
